<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63665">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01781637</url>
  </required_header>
  <id_info>
    <org_study_id>Peanut 002</org_study_id>
    <nct_id>NCT01781637</nct_id>
  </id_info>
  <brief_title>Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial</brief_title>
  <acronym>PRROTECT</acronym>
  <official_title>Phase 2 Study of Omalizumab in Oral Peanut Desensitization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Boston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Boston</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will perform a double blind, placebo controlled clinical trial with Xolair
      (omalizumab) at four centers to safely and rapidly desensitize patients with severe peanut
      allergy. The investigators will determine if pretreatment with anti-IgE mAb
      (Xolair/omalizumab) can greatly reduce allergic reactions and allow for faster and safer
      desensitization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      36 subjects will receive Xolair, and 8 subjects will receive placebo.  The study will occur
      at 4 sites:  Boston Children's Hospital, Children's Hospital of Philadelphia, Stanford
      University and Lurie Children's Hospital.

      Patients will be pre-treated with Xolair or placebo before rapid oral peanut
      desensitization.  Patients will continue to receive Xolair during the 8 subsequent weeks of
      desensitization, receiving their final dose of Xolair one week after reaching the highest
      tolerated dose of peanut.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The ability of omalizumab-treated subjects to successfully complete the build-up phase of peanut, and tolerate daily 4,000 mg doses of peanut flour after discontinuing omalizumab.</measure>
    <time_frame>14 wks after the start of oral peanut desensitization (wk 26 of study).</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The ability of subjects to tolerate an oral dose of 4,000 mg peanut.</measure>
    <time_frame>8 wks after the start of oral peanut desensitization (study wk 20).</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Peanut Allergy</condition>
  <condition>Food Allergy</condition>
  <arm_group>
    <arm_group_label>omalizumab group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive omalizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>subcutaneous injection</description>
    <arm_group_label>omalizumab group</arm_group_label>
    <other_name>Xolair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>subcutaneous injection</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe peanut allergy-sensitive subjects between the ages of 7 to 25
             years old.

          -  Sensitivity to peanut allergen will be documented by a positive skin prick test
             result (6 mm diameter wheal or greater)

          -  ImmunoCAP IgE level to peanut &gt; 10 kU/L.

          -  Sensitivity to peanut allergen based on a double-blind placebo-controlled oral food
             challenge (DBPCFC) at maximum of cumulative 175 mg of peanut protein dose.

        Exclusion Criteria:

          -  Subjects with a total IgE at screening of &lt; 50 kU/L &gt; 2,000 kU/L.

          -  Positive reaction to the placebo on DBPCFC.

          -  Previous reaction to omalizumab.

          -  Subjects having a history of severe anaphylaxis to peanut requiring intubation or
             admission to an ICU, frequent allergic or non-allergic urticaria, or history
             consistent with poorly controlled persistent asthma, or gastrointestinal or
             gastroesophageal disease.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynda C Schneider, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Boston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew MacGinnitie, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Children' Hospital Boston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kari Nadeau, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Spergel, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacqueline Pongracic, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Lurie Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Little</last_name>
    <phone>617-355-6127</phone>
    <email>sara.little@childrens.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lynda C Schneider, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tony Trela</last_name>
      <email>safar.inquiry@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Kari C Nadeau, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maripaz Vazquez, BSN</last_name>
      <phone>312-227-6474</phone>
      <email>MVAZQUEZ@LURIECHILDRENS.ORG</email>
    </contact>
    <investigator>
      <last_name>Jacqueline Pongracic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Immunology, Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney B Rooney</last_name>
      <phone>267-426-8657</phone>
      <email>ROONEYC@EMAIL.CHOP.EDU</email>
    </contact>
    <investigator>
      <last_name>Jonathan Spergel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 3, 2014</lastchanged_date>
  <firstreceived_date>January 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Boston</investigator_affiliation>
    <investigator_full_name>Lynda Schneider</investigator_full_name>
    <investigator_title>Associate Professor, Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>Xolair</keyword>
  <keyword>omalizumab</keyword>
  <keyword>peanut</keyword>
  <keyword>oral desensitization</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Food Hypersensitivity</mesh_term>
    <mesh_term>Peanut Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
